Search results
Pakistan probes distributors of Roche cancer drug after patients go blind
Reuters via AOL· 7 months agoLAHORE, Pakistan (Reuters) -Pakistan said on Monday it was investigating two local distributors of...
Top 15 Best-Selling Cancer Drugs
Insider Monkey via Yahoo Finance· 3 months agoIn this article, we will be discussing the top 15 best-selling cancer drugs. If you are not interested in reading about the global cancer treatment...
Amgen drug extends survival in some inoperable colon cancers
Reuters via Yahoo News· 2 years agoThe following are summaries of some of the cancer research advances being presented the annual...
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
Zacks via Yahoo Finance· 1 year agoImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx,...
What This News Means for Merck
Motley Fool· 2 years agoIn combination with Roche's (OTC: RHHBY) bevacizumab (Avastin), Merck's (NYSE: MRK) oncology medicine -- co-owned with AstraZeneca (NASDAQ: AZN) and...
Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval
Zacks via Yahoo Finance· 10 months agoRoche RHHBY obtained conditional marketing authorization from the European Commission (EC) for its...
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
Zacks via Yahoo Finance· 5 months agoRoche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone...
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
Zacks via Yahoo Finance· 1 year agoRoche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating...
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
Investor's Business Daily· 1 year agoBiotech giant Regeneron Pharmaceuticals said Monday that sales of its linchpin Eylea drug in the...
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
Zacks via Yahoo Finance· 9 months agoRoche Holding AG’s RHHBY performance in the first half was average, as COVID-19 product related...
